Back to top
more

Fusion Networks Holdings Inc. (FUSN)

(Delayed Data from OTC)

$0.00 USD

0.00
NA

0.00 (11.11%)

Updated Jul 21, 2015 09:55 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday

by Zacks Equity Research

Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.

Kinjel Shah headshot

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

by Kinjel Shah

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

Wall Street Analysts Predict a 149.52% Upside in Fusion Pharmaceuticals Inc. (FUSN): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 149.5% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why Fusion Pharmaceuticals Inc. (FUSN) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Fusion Pharmaceuticals Inc. (FUSN) have what it takes to be a top stock pick for momentum investors? Let's find out.

How Much Upside is Left in Fusion Pharmaceuticals Inc. (FUSN)? Wall Street Analysts Think 162%

by Zacks Equity Research

The mean of analysts' price targets for Fusion Pharmaceuticals Inc. (FUSN) points to a 162% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 37.50% and 389.27%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 2.56% and 88.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy

by Zacks Equity Research

Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca.

Fusion Pharmaceuticals Inc. (FUSN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 3.51% and 16.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 30.77% and 0.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics

by Zacks Equity Research

Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.

Corcept (CORT) Thrives on Korlym, Overdependence a Concern

by Zacks Equity Research

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

    Kinjel Shah headshot

    5 Stocks to Bet on in an Innovation-Driven Drug Industry

    by Kinjel Shah

    Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.

    PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US

    by Zacks Equity Research

    The FDA requests additional data to allow PTC Therapeutics (PTCT) to continue enrollment in its phase II PIVOT-HD study evaluating PTC518 for treating Huntington's disease in the United States. Stock down.

    What Makes Fusion Pharmaceuticals Inc. (FUSN) a New Strong Buy Stock

    by Zacks Equity Research

    Fusion Pharmaceuticals Inc. (FUSN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why

    by Zacks Equity Research

    Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

    Pacira (PCRX) Up on Data From Exparel Label Expansion Study

    by Zacks Equity Research

    Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.

    After Plunging 14.9% in 4 Weeks, Here's Why the Trend Might Reverse for Fusion Pharmaceuticals Inc. (FUSN)

    by Zacks Equity Research

    Fusion Pharmaceuticals Inc. (FUSN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

    Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 16.98% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy?

    by Zacks Equity Research

    Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Will Fusion Pharmaceuticals Inc. (FUSN) Report Negative Q2 Earnings? What You Should Know

    by Zacks Equity Research

    Fusion Pharmaceuticals Inc. (FUSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Fusion Pharmaceuticals (FUSN) Jumps: Stock Rises 9%

    by Zacks Equity Research

    Fusion Pharmaceuticals (FUSN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.